相关实验视频
Updated: Jan 14, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
用upadacitinib成功治疗耐火性状血管病变:一个案例报告
Cuiqin Wang1,2,3,4,5, Xiaobing Wang1,2,3,4,5, Pingxiu He1,2,3,4,5
1Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People's Republic of China.
乌帕达西替尼 (Upadacitinib) 在一个患者中有效治疗了耐火性活体血管病变 (LV),显示出症状的快速改善和的愈合. 这种Janus激酶 (JAK) 抑制剂为难以治疗的LV病例提供了一个有希望的新选择.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 活体血管病变 (LV) 是一种罕见的慢性疾病,其特征是疼痛的和紫外线.
- 现有的治疗方法,如托法西提尼布,巴里西提尼布和阿布罗西提尼布显示有效性,但耐火病例需要新的治疗方法.
研究的目的:
- 评估选择性Janus激酶 (JAK) 抑制剂upadacitinib的疗效和安全性,在患有耐治疗活体血管病变 (LV) 的患者中.
主要方法:
- 仅有一名耐火性LV患者接受了上巴西提尼布 (15毫克/天) 治疗.
- 临床反应使用复合得分,疼痛强度等级和治疗前后愈的评估来评估.
主要成果:
- 在24天内观察到临床评分的快速和显著改善,表明缓解.
- 到第52天,疼痛强度显著降低,几乎完全愈合.
- 观察到的唯一不良事件是简单的耳膜疹.
结论:
- 乌帕达西替尼 (Upadacitinib) 显示出作为耐火性活体血管病变 (LV) 患者的新疗法选择的潜力.
- 需要在更大的队列中进行进一步的研究,以证实这些初步发现,并确定upadacitinib在LV管理中的作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment Resistant Cancers
